Germany Cardiovascular Diseases Therapeutics Market Analysis

Germany Cardiovascular Disease Therapeutics Market Executive Analysis

Germany's cardiovascular disease therapeutics market size is at around $5.95 Bn in 2022 and is projected to reach $9.08 Bn in 2030, exhibiting a CAGR of 5.42% during the forecast period. In 2022, Germany's present health expenditure was paid for by transfers and subsidies from the government. According to the Federal Statistical Office (Destatis), this represents a rise of $18.5 Bn, or 32%, from the previous year. Therefore, 16% of the $483,5 Bn in current health expenditure was made up of government transfers and subsidies, an increase of 3% points from the previous year. Since the calculations started in 1992, that was the biggest increase in this kind of financing. Direct federal subsidies to combat the Covid-19 pandemic were the cause of the rise in government transfers and subsidies, which include, for instance, the yearly federal grant to the umbrella health fund and the subsidies from public employers.

The health of the majority of Germans continues to be significantly impacted by cardiovascular disease. For many years, it has been the main cause of mortality in Germany, accounting for 36.1% of deaths in men and 43.9% of deaths in women. The majority of the expenses associated with disease directly affecting the German healthcare system are also attributable to cardiovascular disease. The four most significant cardiovascular diseases - Coronary Heart Disease (CHD), myocardial infarction, stroke, and heart failure - are responsible for more than two-thirds of cardiovascular mortality and roughly half of all cardiovascular hospital diagnoses and total disease expenses.

In addition to serving as an intermediary molecule between DNA and proteins, RNA also functions as a dynamic and adaptable regulator of gene translation, according to a number of lines of evidence. In order to achieve this, biotechnology firms in Germany are presently developing RNA-targeting therapies for use in clinical settings, broadening the universe of "drug-able" targets. The endogenous regulators of gene silencing, small interfering RNAs (siRNAs), and microRNAs (miRNAs) have been researched as possible therapeutics. While miRNA-based therapeutics include miRNA inhibitors and miRNA mimics that, respectively, antagonize and imitate the function of an endogenous miRNA, synthetic siRNAs are used to suppress the expression of the mRNA target. Several clinical trials are presently investigating the therapeutic potential of RNA-targeting therapies in the context of cardiovascular disease therapeutics.

Market Dynamics

Market Growth Drivers

Technology advancements have made it simpler to identify and manage Cardiovascular Disease (CVD). For instance, improved imaging methods are enabling faster and more precise heart disease diagnosis, while minimally invasive techniques are simplifying heart surgery. The efficacy of CVD therapeutics is anticipated to increase due to these technological developments, which will also increase demand. To mitigate the strain that CVD is placing on the healthcare system, the German government is taking action. This includes programs that support healthy lifestyles, such as those that encourage exercise and wholesome eating, as well as funding for studies into CVD. It is anticipated that these efforts will increase the demand in the Germany cardiovascular disease therapeutics market.

Market Restraints

As the patents on the current CVD therapeutics end, generic versions of these medications become accessible. Competing prices and decreased revenue for the pharmaceutical companies that designed the initial drugs can result from this. The regulatory procedure for drug clearance in Germany is stringent and time-consuming. This could slow down the pace at which new medications are introduced to the market and raise the price of developing new medications. The quantity of funding available for CVD therapeutics in Germany may be constrained by the country's limited healthcare budgets. This may make it difficult for some patient populations to obtain care or may reduce the amount of study and development that can be done.

Competitive Landscape

Key Players

• Walter Ritter (DEU)
• AqVida (DEU)
• Vivatis Pharma (DEU)
• Waypharm (DEU)
• Cordes Pharma (DEU)
• Pfizer
• Bayer
• Janssen Pharmaceuticals
• AstraZeneca
• Sanofi
• Novartis

Healthcare Policies and Regulatory Landscape

In Germany, public and private insurance schemes are used to provide healthcare. The bulk of people is covered by the public system, also known as statutory health insurance (SHI), while people who choose private insurance are covered by the private system. The SHI system offers a variety of medical services, including the detection and management of cardiovascular disease (CVD). The Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in Health Care (IQWiG) have stringent rules governing the coverage and payment for treatments for CVD. These groups offer recommendations on the efficacy and value of CVD treatments, which the SHI system uses to determine coverage and reimbursement. For instance, the SHI program pays for the expense of medications used to treat high blood pressure, cholesterol, and antiplatelet agents. The SHI system also includes diagnostic procedures like cardiac catheterization, echocardiograms, and ECGs. Coverage and payment for treatments for CVD are subject to restrictions in some circumstances, though. For instance, there might be waiting lists for certain procedures or eligibility requirements that patients must fulfill before receiving certain treatments. Furthermore, some treatments might not be covered by the SHI system; in such cases, patients might have to pay out of cash or choose private insurance in order to receive these services.